Conditions: Small Cell Lung Carcinoma
Keywords: Small Cell Lung Cancer Extensive stage disease SCLC IGF-1R inhibitor
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 9
Healthy volunteers: no

Brief summary:
This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.

Detailed description:
The study prematurely discontinued on January 26, 2011 due to slow enrollment. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.

Arms:
arm 1: Figitumumab (CP-751,871) Plus Chemotherapy \[Cisplatin (Or Carboplatin) And Etoposide\] All drugs to be administered on a 21 day cycle arm 2: Chemotherapy \[Cisplatin (Or Carboplatin) And Etoposide\] All drugs to be administered on a 21 day cycle

Interventions: intervention 1: figitumumab intervention 2: Cisplatin (Or Carboplatin) intervention 3: Etoposide intervention 4: Cisplatin (Or Carboplatin) intervention 5: Etoposide
Intervention descriptions: intervention 1: Figitumumab (20 mg/kg) intervention 2: Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5 intervention 3: Etoposide (100 mg/m2 IV on Days 1, 2 and 3) intervention 4: Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5 intervention 5: Etoposide (100 mg/m2 IV on Days 1, 2 and 3)

Protocol document: